Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30910926 | 1.00 | ACHE (0.48) | ACHEPKMKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL121801 | 0.83 | TAAR1 (0.43) | ACHEKDM4EALDH1A1SMN1; SMN2TAAR1 | |
| SCHEMBL1072053 | 0.83 | CYP2A6 (0.43) | ACHEALDH1A1TAAR1CYP1A2CYP2A6 | |
| Hydrochloric Acid SCHEMBL29184016 | 0.80 | TAAR1 (0.41) | KDM4EALDH1A1SMN1; SMN2TAAR1GAA | |
| SCHEMBL11029574 | 0.80 | TAAR1 (0.41) | KDM4EALDH1A1SMN1; SMN2TAAR1GAA | |
| SCHEMBL170719 | 0.79 | ACHE (0.50) | ACHEPKMKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22763796 | 0.79 | ACHE (0.50) | ACHEPKMKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL11308408 | 0.77 | ACHE (0.48) | ACHEPKMKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2087457 | 0.77 | ACHE (0.48) | ACHEPKMKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6405863 | 0.77 | ACHE (0.48) | ACHEPKMKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096662-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096660-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096653-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096657-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096658-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096654-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4304588-A1 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| CN-112041296-B | Aminoacetamides containing benzooxy alicyclic structures and uses thereof | 上海璃道医药科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-3394050-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-10-31 | — | — | EP | disclosed |
| US-20170333398-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| EP-3214076-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK ACTIVATING EFFECT | Shionogi & Co., Ltd. (JP) | 2017-09-06 | — | — | EP | disclosed |
| WO-2017109095-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-22 | — | — | US | disclosed |
| US-9556168-B2 | N-alkylated indole and indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| WO-2016068099-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK ACTIVATING EFFECT | 塩野義製薬株式会社 | 2016-05-06 | — | — | WO | disclosed |
| US-20160039842-A1 | OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS | EPIGENETIX, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20150210687-A1 | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2015-07-30 | — | — | US | disclosed |
| US-20130165450-A1 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors | TSUI HON-CHUNG (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210687-A1 | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORC, RORA | ACHE 3884/4885PKM 4457/4885KDM4E 3043/4885 |
| US-20160039842-A1 | OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | ACHE 678/4885PKM 4091/4885KDM4E 435/4885 |
| US-20170333398-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAR2B, PRKAR2A, PRKAG3 | ACHE 3342/4885PKM 1926/4885KDM4E 1094/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | ACHE 3642/4885PKM 514/4885KDM4E 15/4885 |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | ACHE 4821/4885PKM 1759/4885KDM4E 3234/4885 |
| US-20130165450-A1 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors | PDK1, PDPK1, PDK2 | ACHE 4877/4885PKM 61/4885KDM4E 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.